Literature DB >> 11510941

Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance.

V Humbertclaude1, F Rivier, A Roubertie, B Echenne, H Bellet, C Vallat, D Morin.   

Abstract

Hyperprolinemia type I is a deficiency of proline oxidase (McKusick 23950), leading to hyperprolinemia and iminoglycinuria, usually with renal involvement. Hyperprolinemia type I is considered a benign trait. We reported a case of hyperprolinemia type I with a severe neurologic disorder and without renal involvement. The patient had marked psychomotor delay and right hemiparesis. Epilepsy was characterized by status epilepticus or a cluster of seizures. Laboratory findings revealed elevated levels of proline in the serum, urine, and cerebrospinal fluid without delta1-pyrroline 5-carboxylate dehydrogenase in the plasma or urine. Fluorescence in situ hybridization excluded a chromosome 22q11 deletion. Vigabatrin inhibits ornithine transaminase. Thus, vigabatrin could lead to a depletion of the normal pool of pyrroline 5-carboxylate dehydrogenase and could aggravate the clinical condition of the child. In this study, vigabatrin was discontinued. In the following months, the patient had marked psychomotor improvement, without modification of the epilepsy. We suggest that vigabatrin should be avoided in hyperprolinemia type I.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510941     DOI: 10.1177/088307380101600820

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  6 in total

1.  Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia.

Authors:  Steffi van de Ven; Thatjana Gardeitchik; Dorus Kouwenberg; Leo Kluijtmans; Ron Wevers; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

Review 2.  Behavioral and neurochemical effects of proline.

Authors:  Angela T S Wyse; Carlos Alexandre Netto
Journal:  Metab Brain Dis       Date:  2011-06-04       Impact factor: 3.584

3.  Functional consequences of PRODH missense mutations.

Authors:  Hans-Ulrich Bender; Shlomo Almashanu; Gary Steel; Chien-An Hu; Wei-Wen Lin; Alecia Willis; Ann Pulver; David Valle
Journal:  Am J Hum Genet       Date:  2005-01-20       Impact factor: 11.025

4.  Drug off-target effects predicted using structural analysis in the context of a metabolic network model.

Authors:  Roger L Chang; Li Xie; Lei Xie; Philip E Bourne; Bernhard Ø Palsson
Journal:  PLoS Comput Biol       Date:  2010-09-23       Impact factor: 4.475

5.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Saima Kayani; Deepa Sirsi
Journal:  J Cent Nerv Syst Dis       Date:  2012-03-08

6.  Biochemical and clinical features of hereditary hyperprolinemia.

Authors:  Hiroshi Mitsubuchi; Kimitoshi Nakamura; Shirou Matsumoto; Fumio Endo
Journal:  Pediatr Int       Date:  2014-08       Impact factor: 1.524

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.